Oral anticancer drugs: back to square one

Area of Science:

• Oncology
• Clinical Pharmacology
• Drug Administration

Background:

• Tyrosine kinase inhibitors (TKIs) represent a significant advancement in modern cancer treatment.
• Previous concerns regarding the safety of TKIs have been raised, particularly concerning their oral administration.
• The increasing use of oral anticancer medications necessitates a thorough evaluation of their administration and safety.

Purpose of the Study:

• To emphasize and expand upon previously raised concerns regarding tyrosine kinase inhibitors.
• To draw the attention of the clinical pharmacology community to critical issues associated with oral anticancer medication administration.
• To advocate for enhanced safety protocols in the oral delivery of novel cancer therapeutics.

Main Methods:

• Review and commentary on existing literature concerning tyrosine kinase inhibitors.
• Analysis of safety concerns related to the oral administration of anticancer drugs.
• Highlighting critical issues for the clinical pharmacology community.

Main Results:

• Reinforces existing concerns about the 'Playing Russian Roulette' aspect of TKI therapy.
• Identifies additional critical issues beyond those initially highlighted, specifically related to oral administration.
• Underscores the need for greater awareness and vigilance in managing oral anticancer medications.

Conclusions:

• The oral administration of modern anticancer medications, including TKIs, presents significant safety challenges.
• Further attention and research are required to address the critical issues identified.
• Enhanced clinical pharmacology focus is essential for optimizing the safe and effective use of these novel therapies.